IL156282A - Eg-vegf/prokineticin 2-receptor antagonists - Google Patents

Eg-vegf/prokineticin 2-receptor antagonists

Info

Publication number
IL156282A
IL156282A IL156282A IL15628203A IL156282A IL 156282 A IL156282 A IL 156282A IL 156282 A IL156282 A IL 156282A IL 15628203 A IL15628203 A IL 15628203A IL 156282 A IL156282 A IL 156282A
Authority
IL
Israel
Prior art keywords
vegf
prokineticin
nucleic acid
receptor
pharmaceutical composition
Prior art date
Application number
IL156282A
Other languages
English (en)
Other versions
IL156282A0 (en
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of IL156282A0 publication Critical patent/IL156282A0/xx
Publication of IL156282A publication Critical patent/IL156282A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL156282A 2002-06-26 2003-05-03 Eg-vegf/prokineticin 2-receptor antagonists IL156282A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2002129379 DE10229379A1 (de) 2002-06-26 2002-06-26 EG-VEGF Rezeptor Antagonisten

Publications (2)

Publication Number Publication Date
IL156282A0 IL156282A0 (en) 2004-01-04
IL156282A true IL156282A (en) 2010-05-31

Family

ID=29796036

Family Applications (1)

Application Number Title Priority Date Filing Date
IL156282A IL156282A (en) 2002-06-26 2003-05-03 Eg-vegf/prokineticin 2-receptor antagonists

Country Status (7)

Country Link
EP (1) EP1386615B1 (fr)
JP (1) JP4663968B2 (fr)
AT (1) ATE422896T1 (fr)
AU (1) AU2003204933B2 (fr)
DE (2) DE10229379A1 (fr)
ES (1) ES2321822T3 (fr)
IL (1) IL156282A (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589033A4 (fr) * 2003-01-22 2006-04-12 Takeda Pharmaceutical Anticorps et utilisation de ce dernier
GB0320238D0 (en) 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
KR20150084007A (ko) 2012-11-13 2015-07-21 리제너론 파아마슈티컬스, 인크. 항-프로키네티신 수용체 (ｐｒｏｋｒ) 항체 및 이의 용도
WO2018108862A1 (fr) * 2016-12-12 2018-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagoniste du récepteur 2 de la prokinéticine destiné à être utilisé en tant que médicament pour le traitement d'un cancer associé à un vegf

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
WO2000075327A1 (fr) * 1999-06-02 2000-12-14 Genentech, Inc. Methodes et compositions d'inhibition de croissance cellulaire neoplasique
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
DE19841985A1 (de) * 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
AU2002230778A1 (en) * 2000-11-03 2002-05-15 The Regents Of The University Of California Prokineticin polypeptides, related compositions and methods
US6780787B2 (en) * 2002-03-21 2004-08-24 Lam Research Corporation Low contamination components for semiconductor processing apparatus and methods for making components

Also Published As

Publication number Publication date
DE50311184D1 (de) 2009-04-02
AU2003204933A1 (en) 2004-01-15
EP1386615A1 (fr) 2004-02-04
EP1386615B1 (fr) 2009-02-18
IL156282A0 (en) 2004-01-04
JP4663968B2 (ja) 2011-04-06
ATE422896T1 (de) 2009-03-15
JP2004043468A (ja) 2004-02-12
DE10229379A1 (de) 2004-01-29
ES2321822T3 (es) 2009-06-12
AU2003204933B2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
JP5973496B2 (ja) 子癇前症または子癇の診断方法および治療方法
Dogan et al. Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib
US6121230A (en) Anti-VEGF agents in the treatment of endometriosis
US20170242022A1 (en) Methods of diagnosing and treating complications of pregnancy
US7740849B2 (en) Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
Someya et al. Regulation of tight junctions by sex hormones in normal human endometrial epithelial cells and uterus cancer cell line Sawano
KR20090040874A (ko) 임신 합병증의 진단 및 치료 방법
Paunel-Görgülü et al. Trefoil factor family peptide 2 acts pro-proliferative and pro-apoptotic in the murine retina
Fujii et al. Concentrations of receptor for advanced glycation end products, VEGF and CML in plasma, follicular fluid, and peritoneal fluid in women with and without endometriosis
AU2003204933B2 (en) EG-VEGF/prokineticin 2-receptor antagonists
HAGER et al. Developmental regulation of tissue transglutaminase during human placentation and expression in neoplastic trophoblast
Schluesener et al. Spontaneous multidrug transport in human glioma cells is regulated by transforming growth factors type β
Ghosh et al. Target-oriented anti-implantation approaches for pregnancy interception: experiences in the rhesus monkey model
US7432051B2 (en) Erythropoietin and erythropoietin receptor expression in human cancer
Wang et al. CXCR4, regulated by HIF1A, promotes endometrial breakdown via CD45+ leukocyte recruitment in a mouse model of menstruation
Tang et al. Expression and contribution of autophagy to the luteal development and function in the pregnant rats
US20100150930A1 (en) Mage-11 as a marker for endometrial receptivity to embryo transplantation and a marker and therapeutic target in castration-recurrent prostate cancer
EP1301195A2 (fr) Utilisation pharmaceutique de fibuline-1
US20020137680A1 (en) Growth factor expression
Akkad et al. Changes in serum vascular endothelial growth factor following initiation of estrogen replacement after hysterectomy and oophorectomy
Leamon et al. FSH Responsiveness by a Murine Preosteoclastic Cell line
WO2019169113A1 (fr) Compositions et procédés pour le traitement de l'endométriose
Kwok Characterization of the molecular mechanisms underlying the cadherin-mediated differentiation of human trophoblastic cells
Hoshi et al. The effects of activin administration in gonadotropin-deficient (hpg) mice
Smith et al. Endocrinology. First published December 22, 2005 as doi: 10.1210/en. 2005-1073

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees